Blog
RSS FeedPosted by Michael Wonder on 28 May 2020
‘Vaccine nationalism’: a new dynamic in the race to quash coronavirus
27 May 2020 - International pursuit for a shot is shifting into a contest of which world power can immunise its ...
Posted by Michael Wonder on 28 May 2020
Nonparametric statistical analysis
26 May 2020 - Many statistical methods start with a statistical assumption that the distribution of measured values can be summarised ...
Posted by Michael Wonder on 28 May 2020
Modelling epidemics with compartmental models
27 May 2020 - During epidemics, there is a critical need to understand both the likely number of infections and their ...
Posted by Michael Wonder on 28 May 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases announce submission of biologics license application to U.S. FDA for pegunigalsidase alfa for the treatment of Fabry disease
28 May 2020 - Protalix BioTherapeutics together with its development and commercialisation partner Chiesi Global Rare Diseases, today announced the submission ...
Posted by Michael Wonder on 28 May 2020
Cardiff Oncology announces fast track designation granted by the FDA to onvansertib for second-line treatment of KRAS mutated colorectal cancer
28 May 2020 - Fast Track designation for onvansertib in KRAS mutated metastatic colorectal cancer underscores the urgent need for new ...
Posted by Michael Wonder on 28 May 2020
Technegas – US FDA new drug application – next milestone in approval process successfully achieved
27 May 2020 - Cyclopharm is pleased to announce that the Company, through its wholly owned subsidiary Cyclomedica Australia, has been ...
Posted by Michael Wonder on 28 May 2020
Tax payers paid to develop remdesivir but will have no say when Gilead sets the price
27 May 2020 - Critics say government deserves more credit for tens of millions in public money spent to develop coronavirus ...
Posted by Michael Wonder on 27 May 2020
FDA grants priority review of Nucala for patients with hypereosinophilic syndrome
27 May 2020 - An approval would give Nucala a third indication in an eosinophil driven disease. ...
Posted by Michael Wonder on 27 May 2020
U.S. FDA approves Opdivo (nivolumab) and Yervoy (ipilimumab) combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer
26 May 2020 - Approval marks sixth indication for Opdivo and Yervoy-based combinations across five types of cancer. ...
Posted by Michael Wonder on 27 May 2020
Cellectar receives FDA fast track designation for CLR 131 in lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinaemia
26 May 2020 - Cellectar Biosciences today announced the U.S. FDA has granted fast track designation for CLR 131 in lymphoplasmacytic ...
Posted by Michael Wonder on 27 May 2020
FDA approves first treatment for a form of bladder dysfunction in paediatric patients as young as 2 years of age
26 May 2020 - The U.S. FDA today granted approval to VESIcare LS (solifenacin succinate) oral suspension for the treatment of ...
Posted by Michael Wonder on 27 May 2020
FDA approves only drug in U.S. to treat severe malaria
26 May 2020 - Today, the U.S. FDA approved artesunate for injection to treat severe malaria in adult and paediatric patients. ...
Posted by Michael Wonder on 26 May 2020
FDA approves Dupixent (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
26 May 2020 - In the pivotal trial, more than twice as many children achieved clear or almost clear skin and ...
Posted by Michael Wonder on 26 May 2020
Aurinia completes submission of new drug application to the U.S. FDA for voclosporin for the treatment of lupus nephritis
26 May 2020 - Application supported by extensive global clinical program including the pivotal Phase 3 AURORA study and the ...
Posted by Michael Wonder on 26 May 2020
Kala Pharmaceuticals announces FDA acceptance of new drug application for Eysuvis for dry eye disease
26 May 2020 - FDA sets PDUFA goal date of 30 October 2020. ...